An association between adropin hormone and total testosterone in obese men: a case-control study

Asmaa A. Muhammed1*, Rania M. H. M. Eid1, Wafaa Salah Mohammed2 and Mahmoud R. Abdel-Fadeil3

Abstract
Background: Obesity is associated with low testosterone levels that could be caused by many mechanisms. Adropin, a peptide hormone, its levels are decreased in obesity and its receptors are expressed in the hypothalamus, the pituitary gland, and the testis. Adropin association to total testosterone in obese men is not detected yet. This study tries to find out possible associations between serum levels of adropin, adiponectin, total testosterone, and lipid profile in obese men.

Methods: Serum levels of adropin, adiponectin, total testosterone, and lipid profile parameters were measured in 43 obese men and 40 age-matched normal-weight men.

Results: Adropin, adiponectin, and testosterone levels were significantly lower in obese men versus normal-weight men. In all participants, positive correlations between adropin, adiponectin, and total testosterone were detected. Adropin is considered a predictor risk factor for testosterone.

Conclusions: This study suggests a possible causal relationship between adropin and total testosterone which needs further investigation.

Trial registration: Clinicaltrials.gov NCT03724825, registered October 30th, 2018.

Keywords: Adropin, Adiponectin, Total testosterone, Obesity

Background
Obesity is a worldwide increasing problem, which is caused mainly by a positive energy balance in the form of increased energy intake than energy expenditure [1]. Obesity is linked to many health consequences as dyslipidaemia, diabetes mellitus, hypertension, and low testosterone levels in men [2]. Low testosterone levels not only predispose to infertility but also are considered biomarkers for mortality and morbidity in men [3]. Decreased muscle mass and bone mineral density [4], increased insulin resistance, risk of diabetes mellitus, low high-density lipoprotein cholesterol (HDL-c) levels, high triglycerides (TG) levels, hypertension, atherosclerosis, and myocardial infarction all are related to low testosterone levels [5]. Obesity can alter testosterone levels by many mechanisms. However, the exact mechanism is highly complex [6]. Adipokines, cytokines, and inflammation play a role in decreasing testosterone levels in obesity [7]. High aromatase enzyme expression that converts testosterone to oestrogen also affects testosterone levels by negative inhibition on the hypothalamic-pituitary-gonadal (HPG) axis [8]. Also, obesity-associated oxidative stress can injure testicular tissues and decrease testosterone levels [9].

*Correspondence: Asmaa.ali@med.aswu.edu.eg

1 Departments of Medical Physiology, Faculty of Medicine, Aswan University, Aswan 81511, Egypt

Full list of author information is available at the end of the article
Adropin, a 76 amino acid peptide hormone, was first discovered by Kumar et al [10] in obese mice during the microarray analysis of liver gene expression. It is encoded by the energy homeostasis-associated (Enho) gene [10], which is expressed in various organs such as the brain, liver, kidney, heart, pancreas, and human umbilical vein [11]. The orphan G protein-coupled receptor (GPR 19) is present in several tissues as the hypothalamic nuclei, the cerebellum, the testis, the heart, the liver, and the kidneys [12]. It is suggested to be the possible site of adropin action [13]. Adropin plays a role in energy homeostasis through the control of glucose and fatty acid metabolism [14]. It also has an anti-inflammatory [15] and an anti-oxidant effect [16]. In addition, it is described as a membrane-bound protein that binds with NB-3 and activates the Notch1 signaling pathway in the brain which is required for normal cerebellar development [17].

Adropin was found to decrease in obese subjects compared to overweight and normal-weight subjects, and its level negatively correlated with body mass index (BMI) [18]. Intra-peritoneal adropin administration to diet-induced obese (DIO) rats reduced total cholesterol (TC), TG, and low-density lipoprotein cholesterol (LDL-c) levels and increased HDL-c levels [15].

Lower adiponectin levels were detected in obese subjects than in the normal-weight subjects [19–21]. Circulating adiponectin levels showed a positive correlation with HDL-c and a negative correlation with TG and very-low-density lipoprotein (VLDL) levels [22]. Adiponectin can regulate testosterone secretion possibly through acting on the HPG axis [23]. Adiponectin inhibits gonadotrophin-releasing hormone (GnRH) release from the hypothalamus and luteinizing hormone (LH) release from the pituitary gland [24]. In addition, it can directly affect testosterone levels by acting on the testis, as adiponectin receptor 1 (Adipo R1) and adiponectin receptor 2 (Adipo R2) were identified in the testis [25].

Several mechanisms can affect testosterone levels, Adropin hormone may play a role however, up to our knowledge no previous literature clarified the relation between adropin and testosterone levels in normal-weight and obese men. This study aims to find out possible relations between adropin, adiponectin, lipid profile parameters, and total testosterone levels in normal-weight and obese men.

Methods
This case-control study aims to find possible associations between total testosterone, adropin, adiponectin, and lipid profile parameters. 43 obese Egyptian men were included in this study (BMI ≥ 30 kg/m2) and age-matched 40 normal-weight men (BMI ≥18.5 and ≤ 25 kg/m2). The sample size was calculated by G Power 3 software [26] to detect an effect size of 0.2 in the mean adropin and/or adiponectin levels, with an α error probability of 0.05 and 80% power.

Included in this study were men aged from 18 years to 50 years. Subjects with known diabetes mellitus, hypertension, heart failure, kidney diseases, liver diseases, smokers, and subjects with a history of obstructive sleep apnea were excluded.

Blood samples were collected from obese and normal-weight men after fasting for 8-12 hours. Blood was centrifuged at 3000 rpm for 15 minutes to separate serum. The clear, non-haemolysed supernatant was separated and stored at -20°C until analysis. Total serum testosterone levels were measured by VIDAS Testosterone kits (Catalog No. 414320) purchased from Biomerieux, SA, France by Enzyme-linked fluorescent assay (ELFA) technique with intra-assay: coefficient of variability (CV)< 8% and inter-assay: CV ≤ 12% for samples with a concentration between 0.3 ng/mL and 3 ng/mL and CV ≤ 10% for samples with a concentration greater than 3 ng/mL. Enzyme-Linked immunosorbent assay (ELISA) technique using kits purchased from SinoGeneClon Biotech Co., Ltd., China. were used to measure adropin (Catalog No. SG-11595) with a sensitivity: 0.5 ng/ml, intra-assay: CV < 8%, and inter-assay: CV <10%, and serum adiponectin levels (Catalog No. SG-10421) with a sensitivity: 5 ng/ml, intra-assay: CV < 8%, and inter-assay: CV <10%. Fast- ing serum blood glucose, TC, TG, and HDL-c levels were determined by the enzymatic colorimetric method by kits purchased from Biotecnica instruments S.p.A, Italy. The equation described by Friedewald et al [27] was used to determine serum LDL-c levels.

Statistical analysis
Values were analysed using Statistical Package for Social Sciences (SPSS) version 26. The collected data were subjected to the Shapiro–Wilk test for testing normality. If the distribution was normal, the data were expressed as mean ± standard deviation, an independent t test, and Pearson correlation tests were used; however, if the distribution was not normal, the data were expressed as median and interquartile range, Mann–Whitney U test and Spearman correlation tests were applied.

Results
Serum levels of TC, TG, and LDL-c were significantly higher, while HDL-c levels were significantly lower in obese when compared to normal-weight men (P < 0.05 for all). Significantly lower total testosterone, adropin, and adiponectin levels were detected in obese compared to normal-weight men (P < 0.05 for all) (Table 1).

Correlation analysis in normal-weight and obese men detected that BMI showed significant negative
correlations with adropin, adiponectin, and total testosterone levels ($P < 0.05$ for all). Adropin had significant negative correlations with TC, TG, and LDL-c levels ($P < 0.05$ for all) but had a significant positive correlation with HDL-c levels ($P < 0.05$). Adiponectin showed significant negative correlations with TC, TG, and LDL-c levels ($P < 0.05$ for all), and a significant positive correlation with HDL-c levels ($P < 0.05$). Total testosterone was negatively correlated with TC, TG, and LDL-c levels ($P < 0.05$ for all), but positively correlated with HDL-c levels ($P < 0.001$) (Table 2).

Significant positive correlation between adropin and total testosterone levels was determined ($r = 0.383, P < 0.001$) (Fig. 1). Adiponectin correlated positively with total testosterone levels ($r = 0.325, P < 0.01$) (Fig. 2) and positively with adropin ($r = 0.720, P < 0.001$) (Fig. 3).

By multivariate stepwise regression analysis, the independent predictors of serum adropin level by BMI in order are HDL-c ($B = -0.665, P < 0.01$), adropin ($B = 0.065, P < 0.005$), and TG ($B = -0.285, P < 0.001$) (Table 3), while adiponectin, TC and LDL-c showed insignificant association with adropin ($P > 0.05$ for all) (not shown on table).

The independent predictors of serum adropin level by multivariate stepwise regression analysis, according to BMI levels in order are adropin ($B = 0.009, P < 0.001$), and TG ($B = -0.022, P < 0.05$) (Table 4), while testosterone, TC and LDL-c showed insignificant association with adropin ($P > 0.05$ for all) (not shown on table).

The independent predictors of serum adiponectin level is adropin ($B = 70.838, P < 0.001$) (Table 5), while testosterone, TC, TG and LDL-c showed insignificant association with adiponectin ($P > 0.05$ for all) (not shown on table).
Fig. 1 Correlation between adropin and total testosterone levels in normal-weight and obese men

R: Linear = 0.147
r = 0.383
P < 0.001

Fig. 2 Correlation between adiponectin and total testosterone levels in normal-weight and obese men

R: Linear = 0.106
r = 0.325
P < 0.01
TG levels, has been linked to lower testosterone levels [32]. Decreased adiponectin secretion from adipose tissue may also play a role [7]. High aromatase enzyme expression, which converts testosterone to oestrogen, lowers testosterone levels via HPG axis negative inhibition [8]. Furthermore, obesity-related increases in TNF- can directly inhibit LH secretion [33].

This study found a significant positive correlation between adropin and total testosterone. Furthermore, stepwise regression analysis showed that HDL-c, adropin, and TG are significant predictors of testosterone levels. In line with this, Fernández-Miró et al [5] discovered that low testosterone levels were associated with low HDL-c and high TG levels in men, and Hagiuda et al [32] found that TG was a significant risk factor for decreased serum testosterone levels in men. To our knowledge, no previous study has described the relationship between adropin and testosterone in men.

---

**Table 3** Multivariate stepwise regression analysis showing significant predictors of total testosterone

| Variables       | B ± SE  | 95% CI for B | P    |
|-----------------|---------|--------------|------|
| HDL-c (mg/dl)   | 0.065 ± 0.019 | 0.028 – 0.103 | 0.001|
| Adropin (ng/ml) | 0.034 ± 0.014 | 0.006 – 0.063 | 0.019|
| TG (mg/dl)      | -0.005 ± 0.002 | -0.009 – -0.0003 | 0.036|

**Table 4** Multivariate stepwise regression analysis showing significant predictors of adropin

| Variables       | B ± SE  | 95% CI for B | P    |
|-----------------|---------|--------------|------|
| Adiponectin (ng/ml) | 0.009 ± 0.001 | 0.007 – 0.010 | <0.001|
| TG (mg/dl)      | -0.022 ± 0.010 | -0.042 – -0.003 | 0.027|

**Table 5** Multivariate stepwise regression analysis showing significant predictors of adiponectin

| Variable       | B ± SE  | 95% CI for B | P    |
|----------------|---------|--------------|------|
| Adropin (ng/ml) | 70.838 ± 5.683 | 59.532 – 82.145 | <0.001|

B: B coefficient; SE Standard error; 95% CI 95% confidence interval; R square for the model is 0.317; P: significance. P is significant if < 0.05; HDL-c High-density-lipoprotein cholesterol, TG Triglycerides

---

**Fig. 3** Correlation between adiponectin and adropin levels in normal-weight and obese men

R: Linear = 0.657
r = 0.720
P < 0.001
Adropin may influence testosterone levels by affecting TG levels. Adropin administration to rats decreased TG synthesis [34], implying that lower adropin levels in obesity are associated with higher TG levels, which are considered a significant predictor of testosterone levels, as mentioned in this study and the Hagiuda et al [32] study.

Adropin administration decreased TNF-α levels in streptozotocin-induced type 2 diabetic rats [15]. Obesity is associated with low adropin levels and high TNF-α levels which inhibit LH production and decrease total testosterone levels [35]. Besides that, high oxidative stress levels associated with low adropin [16] are linked to low testosterone levels [36].

Adropin has been identified as a predictor risk factor for adiponectin levels in this study, which is supported by Kumar et al [10] who demonstrated that adropin injection in mice increased serum adiponectin levels. Adropin directly increased adiponectin mRNA expression in rat adipocytes [37]. Besides that, adropin administration in streptozotocin-induced type 2 diabetic rats decreased TNF-α levels [15]. Obesity-associated low adropin levels are related to high TNF-α levels, which act on adipocytes decreasing adiponectin mRNA stability and expression, resulting in decreased adiponectin formation [38]. Thus low adropin levels associated with obesity could modulate testosterone levels by decreasing adiponectin levels.

Adiponectin could influence testosterone secretion by acting on the HPG axis [23]. It inhibits hypothalamic GnRH secretion as well as pituitary LH release [24]. Adiponectin receptors were discovered in the testis [25], and its administration to rats reduced testosterone levels in the testis [39]. This study revealed a positive association between adiponectin and testosterone. Thomas et al [40] found a positive correlation between adiponectin and testosterone in normal-weight and obese adult men. Riestra et al [41] found a negative but not significant correlation between adiponectin and testosterone in normal-weight adolescents. Furthermore, Song et al [42] found no significant correlation between adiponectin and testosterone in normal-weight old men. This could be explained by differences in testosterone levels across age groups, which affect adiponectin levels.

In this study, obese men had significantly lower adiponectin levels than normal-weight men, which is consistent with Thanakun et al [20] and Li et al [21], who found lower adiponectin levels in obese subjects. Obesity-associated low adiponectin levels could reduce adiponectin inhibition on GnRH and LH secretion, increasing testosterone levels [24]. However, adiponectin can affect testosterone in other ways, as illustrated below: Obesity-related low adiponectin levels raise TG levels by decreasing TG catabolism [22], which is a significant risk factor for low testosterone levels in men [32]. TNF-α production in the liver is reduced by adiponectin [43]. As a result, lower adiponectin levels in obesity may be associated with increased TNF-α production, which directly inhibits pituitary LH secretion [35]. Low adiponectin levels have been linked to high levels of oxidative stress [44], which may further reduce testosterone levels [36]. Although low adiponectin levels can increase testosterone levels when acting directly on the hypothalamus, pituitary, and testis, it can also decrease testosterone levels by increasing TG levels, TNF-α, and oxidative stress levels. The sum of these mechanisms could be the net effect of adiponectin on testosterone.

Another way adropin can affect testosterone is by acting directly on the hypothalamus, affecting GnRH secretion. Loewen and Ferguson [45] discovered that the majority of cells in the paraventricular nucleus responded to adropin bath application via depolarization or hyperpolarization. More studies are needed to determine the precise effect of adropin on GnRH secretion. Concerning the effect of adropin on the pituitary gland and the testis, Hoffmeister-Ullerich et al [12] discovered GPR19 expression in the pituitary gland and testis of mice, implying a possible adropin role in the pituitary gland and the testis. The exact effect of adropin on LH and testosterone secretion requires further research.

This study has several limitations that must be addressed. This study did not rule out hypothyroidism or hyperthyroidism, both of which can affect lipid profile levels. Furthermore, adiponectin, adropin, and testosterone levels may be affected by age. Participants in this study ranged in age from 18 to 50 years old; smaller age groups may be required to test the effects of age on these parameters. Future research is needed to confirm the effect of adropin on testosterone levels, which could be accomplished by injecting adropin into rats or culturing testicular, pituitary, or hypothalamic tissues with adropin, both of which were unavailable to the authors at the time of the study.

**Conclusion**

Many factors contribute to obesity-related low testosterone levels. Adropin hormone was discovered to be a predictor risk factor of testosterone in this study, implying that adropin may play a role in influencing testosterone levels. This could be accomplished by affecting TG and adiponectin levels. More research is needed to determine exactly how adropin affects testosterone levels.

**Abbreviations**

HDL-c: High-density lipoprotein cholesterol; TG: Triglycerides; HPG: Hypothalamic-pituitary-gonadal; Enho: Energy homeostasis-associated; GPR: G protein-coupled receptor; BMI: Body mass index; DIO: Diet-induced obese; TC: Total cholesterol; LDL-c: Low-density lipoprotein cholesterol; VLDL: Very-low-density lipoprotein; GnRH: Gonadotrophin-releasing hormone; LH: Luteinizing hormone; Adipo R1: Adiponectin receptor 1; Adipo R2: Adiponectin receptor 2; ELISA: Enzyme-Linked immunosorbent assay; (CV): Coefficient of variability.
Acknowledgements
Not applicable.

Authors’ contributions
AA and MR conceived and designed the research. AA conducted experiments. WS contributed new reagents and analytical tools. RM analysed data. AA and MR wrote the manuscript. All authors read and approved the manuscript.

Funding
Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF), in cooperation with The Egyptian Knowledge Bank (EKB). This study was funded by the Faculty of Medicine, Aswan University, Aswan, Egypt.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interest
The authors declare that they have no competing interests.

Ethics approval and consent to participate
This study was approved by the ethics committee of the Faculty of Medicine, Assiut University, Assiut, Egypt. 2 Department of Clinical Pathology, Faculty of Medicine, Asswan University, Aswan, Egypt. 3 Departments of Medical Physiology, Faculty of Medicine, Aswan University, Aswan 81511, Egypt. 4 Department of Medical Physiology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Consent for publication
Not applicable.

Author details
1 Departments of Medical Physiology, Faculty of Medicine, Assiut University, Assiut, Egypt. 2 Department of Clinical Pathology, Faculty of Medicine, Asswan University, Aswan, Egypt. 3 Departments of Medical Physiology, Faculty of Medicine, Assiut University, Assiut, Egypt.

Received: 13 April 2022 Accepted: 14 July 2022
Published online: 27 July 2022

References

1. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.
2. Hruby A, Manson JE, Qi L, Malik VS, Rimm EB, Sun Q, et al. Determinants and consequences of obesity. Am J Public Health. 2016;106(9):1656–62.
3. Morgentaler A, Minar MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224–51.
4. Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Ellenberg SS, Matsumoto AM, et al. Association of sex hormones with sexual function, vitality, and physical function of symptomatic older men with low testosterone levels at baseline in the testosterone trials. J Clin Endocrinol Metab. 2015;100(3):1146–55.
5. Fernández-Miró M, Chillarón JJ, Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Medicina Clínica (English Edition). 2016;146(2):69–73.
6. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism pathophysiology, clinical implications and management. Eur Endocrinol. 2019;15(2):83.
7. Tsatsanis C, Dzmitrazka E, Avgoustinakis P, Malliaraki N, Mytaras V, Margioris AN. The impact of adipose tissue-derived factors on the hypothalamic-pituitary-gonadal (HPG) axis. Hormones. 2015;14(4):549–62.
8. Kelly D, Jones T. Testosterone and obesity. Obes Rev. 2015;16(7):581–606.
9. Zhao J, Zhai L, Liu Z, Wu S, Xu L. Longevity c. Leptin level and oxidative stress contribute to obesity-induced low testosterone in murine testicular tissue. Oxid Med Cell Longev. 2014;2014:1–14.
31. Amjad S, Baig M, Zahid N, Tariq S, Rehman RJA. Association between leptin, obesity, hormonal interplay and male infertility. Andrologia. 2019;51(1):e13147.

32. Hagiuji T, Ishikawa H, Furuyuki T, Hanawa Y, Marumo KJA. Relationship between dyslipidaemia and semen quality and serum sex hormone levels: an infertility study of 167 Japanese patients. Andrologia. 2014;46(2):131–5.

33. Huang G, Yuan M, Zhang J, Li J, Gong D, Li Y, et al. IL-6 mediates differentiation disorder during spermatogenesis in obesity-associated inflammation by affecting the expression of Zfp663 through the SOCS3/STAT3 pathway. Sci Rep. 2016;6(1):1–11.

34. Gao S, Ghozhal S, Zhang L, Stevens JR, McComnis KS, Finck BN, et al. The peptide hormone adiponectin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem. 2019;294(36):13366–77.

35. Lamm S, Chidakel A, Bansal R. Obesity and hypogonadism. Urol Clin. 2016;43(2):239–45.

36. Abbasi-Hormozi S, Babapour V. Stress hormone and oxidative stress biomarkers link obesity and diabetes with reduced fertility potential. Cell J (Yakhteh). 2019;21(3):307.

37. Jasaszwili M, Pruszyńska-Oszmalkiewicz T, Strowski MZ, Nowak KW, Skrzypski M. Adiponectin Slightly Modulates Lipolysis, Lipogenesis and Expression of Adipokines but Not Glucose Uptake in Rodent Adipocytes. Genes. 2021;12(6):914.

38. Wang Y, Wang H, Hegde V, Dubuisson O, Gao Z, Dhurandhar NV, et al. Interplay of pro- and anti-inflammatory cytokines to determine lipid accrution in adipocytes. Int J Obes. 2013;37(11):1490–8.

39. Pfleger A, Nanjappa MK, Coleyman ES, Mansour M, Wanders D, Plaisance EP, et al. Regulation of adiponectin secretion by soy isoflavones has implications for endocrine function of the testis. Toxicol Lett. 2012;209(1):78–85.

40. Thomas S, Kratzsch D, Schaaf M, Schmolz M, Grunewald S, Thiery J, et al. Seminal plasma adipokine levels are correlated with functional characteristics of spermatozoa. Fertil Steril. 2013;99(5):1256–63. e3.

41. Riestra P, García-Anguita A, Ortega L, García C. Relationship of adiponectin with sex hormone levels in adolescents. Horm Res Paediatr. 2013;79(5):1256–63. e3.

42. Song HJ, Oh S, Quan S, Ryu O-H, Jeong J-Y, Hong K-S, et al. Gender differences in adiponectin levels and body composition in older adults. Hallym aging study. BMC Geriatr. 2014;14(1):1–8.

43. Xu A, Wang Y, Keshaw H, Xy O-H, Jeong J-Y, Hong K-S, et al. Gender differences in adiponectin levels and body composition in older adults. Hallym aging study. BMC Geriatr. 2014;14(1):1–8.

44. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7(1):1–8.

45. Loewen SP, Ferguson AV. Integrative Physiology C. Adipin acts in the rat Paraventricular nucleus to influence neuronal excitability. Am J Physiol Regul Integr Comp Physiol. 2017;312(4):RS11–R9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.